Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Spark Therap (NQ: ONCE )

N/A USD UNCHANGED
Last Price Updated: 12:31 PM EST, Dec 17, 2019 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Spark Therap

< Previous 1 2 3 4 5 6 Next >
Spark Therapeutics to Host Conference Call on Thursday, Nov. 3 at 8:30 a.m. to Discuss Third Quarter 2016 Results
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Collaboration with Leading Gene Therapy Center at University of Massachusetts Medical School
Multi-year collaboration focuses on selecting adeno-associated virus vectors to target debilitating genetic diseases in cells of the retina, liver and central nervous system 
From GlobeNewswire News Releases
Data Presented Today at the American Academy of Ophthalmology 2016 Annual Meeting Reinforce Efficacy and Durability of Voretigene Neparvovec in RPE65-Mediated Inherited Retinal Disease
Statistically Significant Results for Visual Field Highlighted for the First Time 
From GlobeNewswire News Releases
Covered Call reports for ACADIA Pharmaceuticals, Spark Therapeutics, Valero Energy, Lululemon and CSX include trade ideas that offer returns of 20% or more!
InvestorsObserver issues critical PriceWatch Alerts for ACAD, CSX, LULU, ONCE, and VLO. 
From PR Newswire
Spark Therapeutics Launches Initiative to Improve Access to Genetic Testing for Inherited Retinal Diseases
Free Genetic Test Helps Eligible Patients in U.S. Affected by Certain Progressive Retinal Diseases Get Support and Information 
From GlobeNewswire News Releases
Spark Therapeutics to Participate in AAO Annual Meeting
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering... 
From GlobeNewswire News Releases
NVIDIA trade offers an 8% return in 53 days, or find similar option trades on GW Pharmaceuticals, Consol Energy, Micron, and Spark Therapeutics
InvestorsObserver issues critical PriceWatch Alerts for CNX, GWPH, MU, NVDA, and ONCE. 
From PR Newswire
Spark Therapeutics to Participate in Multiple Upcoming Conferences
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering... 
From GlobeNewswire News Releases
Covered Call reports for Spark Therapeutics, Potash Corporation of Saskatchewan, GNC Holdings, Weight Watchers and Intersil Corporation include trade ideas that offer returns of 20% or more!
InvestorsObserver issues critical PriceWatch Alerts for GNC, ISIL, ONCE, POT, and WTW. 
From PR Newswire
Spark Therapeutics to Participate in Multiple September Conferences
Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments,... 
From GlobeNewswire News Releases
Spark Therapeutics Reports Second Quarter 2016 Financial Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE) today announced financial results for the quarter ended June 30, 2016 and updated investors on its progress. 
From GlobeNewswire News Releases
Spark Therapeutics Announces New Positive Data from Continuation of Phase 3 Trial of Voretigene Neparvovec
Spark Therapeutics (NASDAQ:ONCE) today announced new data from the continuation of the Phase 3 trial of voretigene neparvovec (formerly referred to as SPK-RPE65), its most advanced product candidate.... 
From GlobeNewswire News Releases
Chipotle Mexican Grill, Mercadolibre Incorporated, Spark Therapeutics, Quanta Services Inc., and Nike and more offer option-trading opportunities that offer returns of more than 20%
InvestorsObserver issues critical PriceWatch Alerts for CMG, MELI, NKE, ONCE, and PWR. 
From PR Newswire
Spark Therapeutics, Inc. to Host Conference Call on August 10th at 8:30a.m. to Discuss Second Quarter 2016 Results
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, August 10, 2016 at 8:30 a.m. ET to report corporate and financial results for the three and six months... 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
First four subjects all with follow up beyond 12 weeks without any need for immunosuppression 
From GlobeNewswire News Releases
Biotechnology Stocks Technical Data -- EPIRUS Biopharma, Ampio Pharma, Spark Therapeutics, and Lion Biotechnologies
From PR Newswire
Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B
Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Participation in Conferences in July
Spark Therapeutics (NASDAQ:ONCE) announced today that it will participate in the following conferences in July: 
From GlobeNewswire News Releases
Spark Therapeutics Announces Publication of Positive Follow-Up Data from Phase 1 Trial of Voretigene Neparvovec in The Lancet
Study provides insight into long-term safety and durability of effect of contralateral-eye administration in subjects with childhood-onset blindness caused by RPE65 mutations 
From GlobeNewswire News Releases
Spark Therapeutics Announces Closing of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the closing of its previously announced underwritten public offering of common stock pursuant to an automatically effective shelf... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Pricing of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today the pricing of an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective shelf... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Launch of Public Offering
Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that it has commenced an underwritten public offering of 3,500,000 shares of its common stock pursuant to an automatically effective... 
From GlobeNewswire News Releases
Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity
Spark Therapeutics (NASDAQ:ONCE) announced today updated results of the first cohort from the ongoing Phase 1/2 clinical trial of SPK-9001, the lead investigational candidate in its SPK-FIX program,... 
From GlobeNewswire News Releases
Spark Therapeutics, Inc. to Host Conference Call on Monday June 13th at 8:30 a.m. to Discuss SPK-9001 Phase 1/2 Data for the Treatment of Hemophilia B Presented at EHA
Company also will provide an update on preclinical data on SPK-FVIII for the treatment of Hemophilia A 
From GlobeNewswire News Releases
Spark Therapeutics Announces Participation and Attendance for Conferences in June
Spark Therapeutics (NASDAQ:ONCE) announced today that members of its management team will participate in and attend the following conferences in June: 
From GlobeNewswire News Releases
Spark Therapeutics and Pfizer Announce Data from Initial Subjects in Hemophilia B Trial Demonstrating Consistent Therapeutic Levels of Factor IX Expression
Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that new data will be presented on June 11 at the European Hematology Association’s (EHA) 21st Congress. These data will show... 
From GlobeNewswire News Releases
Spark Therapeutics Reports First Quarter 2016 Financial Results and Recent Business Highlights
Spark Therapeutics (NASDAQ:ONCE) today announced financial results for the quarter ended March 31, 2016 and updated investors on its progress. 
From GlobeNewswire News Releases
Spark Therapeutics Announces Multiple Presentations at Upcoming Investor Meetings
Spark Therapeutics (NASDAQ:ONCE) today announced that members of its management team will participate in three upcoming conferences in May: 
From GlobeNewswire News Releases
Spark Therapeutics Announces Multiple Presentations at Upcoming Scientific Meetings
Spark Therapeutics (NASDAQ:ONCE) today announced that researchers will make multiple presentations related to the company’s broad gene therapy development portfolio at upcoming scientific meetings. 
From GlobeNewswire News Releases
Spark Therapeutics, Inc. to Host Conference Call on May 4th at 8:30a.m. to Discuss First Quarter 2016 Results
Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, May 4, 2016 at 8:30 a.m. ET to report corporate and financial results for the three months ended March... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.